Come check out one of Integra Connect PrecisionQ’s poster presentations at ESMO at the Messe Berlin in Berlin, Germany today, Monday, October 20, 2025, from 12:00-12:45 CEST. This poster presents: Real-World study on rates of positivity for ESR1, PIK3CA, PTEN, and ATK1 among ER+/HER2- metastatic breast cancer patients The real-world analysis shows that nearly 50% of patients harbor either PTEN, AKT1, or PIK3CA mutations with nearly a third of those patients also harboring an ESR1 mutation. The results underscore the importance for healthcare providers to implement routine Next Generation Sequencing testing at disease progression to identify relevant biomarkers to direct guideline concordant care. Poster 527P / Abstract 3856 Link to Abstract: https://lnkd.in/eNjRE-Jf Authors: Michael Gart | Erin Alwon | Ashley Lamb | Kristen Henn | Prateesh Varughese PharmD MBA | Brandon Wang | Lisa M. | Robert Geller | Jeffrey Scott
